Results Aventis Pharms, Inc. et al. v. Barr Labs, Inc. et al.

Aventis Pharms, Inc. et al. v. Barr Labs, Inc. et al.

(01-3627-JAG) (D NJ). Patent infringement action regarding Barr Laboratories’ ANDA for Aventis’s allergy product Allegra® (fexofenadine hydrochloride). Successful opposition to preliminary injunction and successful launch at risk for Barr.

View All Results

Every case is different and results depend on their specific circumstances. Prior results do not guarantee a similar outcome.

"*" indicates required fields

Name*

First Last

Phone Number*

Email Address*

How can we help you?*

This field used to prevent automated submissions, do not fill out

This field is for validation purposes and should be left unchanged.

Federal Circuit Refuses to Consider Disease Variants as Species of a Disease Genus for Method of Treatment Patents
A Proposal to Address the U.S. Patent “Thicket” Problem During Examination
Capuano IP Launches New Website
Alnylam Pharms, Inc. v. Dicerna Pharms, Inc. (15-04126-EPL) (Mass. Sup. Ct.)

120 Washington St.
Salem, MA 01970

Attorney Advertising | Disclaimer | Privacy Policy
Website developed in accordance with Web Content Accessibility Guidelines 2.1.
If you encounter any issues while using this site, please contact us: 703.992.4580